Therapeutic nanocarriers comprising extracellular matrix-inspired peptides and polysaccharides

Translating osteoarthritis genetics research: challenging times ahead

“…These data can now stimulate investigations into the practicalities of such interventions. Fortunately, the OA research community has considerable experience in recruiting to OA trials, in delivering agents to relevant joint tissues, and in measuring appropriate clinical parameters to assess DMOAD efficacy [3,4,[30][31][32][33][34][35][36][37][38]69]. New technologies and OA biomarkers are constantly being developed that will aid these investigations [70][71][72][73][74].…”

“…This synovial fluid reduces friction between the cartilage of the bones during movement and supplies nutrients and oxygen to this avascular tissue. The cavity and fluid have been exploited to deliver, via a range of agents to the joint tissues, including engineered cells secreting anabolic growth factors, extracellular vesicles with small-molecule cargoes, and nanoparticles linked to anticatabolic agents [30][31][32][33][34][35][36][37][38]. The latter have been functionalized with a type II collagen antibody, the most abundant collagen of cartilage, to concentrate the therapeutic agent to that tissue [37].…”

Natural biomimetic nano-system for drug delivery in the treatment of rheumatoid arthritis: a literature review of the last 5 years

“…In recent years, significant advancements have been made in the field of RA treatment with regards to extracellular vesicles (EVs) ( 37 , 38 ). These membrane-bound vesicles derived from various cells, play a crucial role as messengers in inter-cellular communication and the regulation of various pathophysiological conditions.…”